{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-25-000120","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2025-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.793373+00:00","generated_at":"2026-05-20T21:54:25.032208+00:00","sec_items":["5.02","5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Neurocrine holds 2025 annual meeting; shareholders approve new equity plan and amended ESPP","bullets":["Four Class II directors elected for three-year terms expiring 2028: Kyle Gano, Richard Pops, Shalini Sharp, Stephen Sherwin (each >72M votes).","Advisory say-on-pay approved: ~78M for, ~6M against, ~1.7M abstentions.","2025 Equity Incentive Plan approved: ~72.6M for, ~12.9M against.","Amended and Restated 2018 ESPP approved: ~85.4M for, ~138K against.","Ratification of Ernst & Young as independent auditor for FY2025 approved: ~85M for, ~5.2M against."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-25-000120","json":"https://secwatch.observer/filing/0000914475-25-000120.json","markdown":"https://secwatch.observer/filing/0000914475-25-000120.md","text":"https://secwatch.observer/filing/0000914475-25-000120.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000120/0000914475-25-000120-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000120/nbix-20250521.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T21:54:25.032208+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}